Comparing Three Different Anti-Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC : A Prospective Study
© 2024 The Authors..
Introduction: Multiple programmed death-ligand 1 (PD-L1) immunohistochemistry assays performed using different antibodies including DAKO 22C3, DAKO 28-8, and Ventana SP142 PD-L1-predictive markers for response to various immune checkpoint inhibitors in NSCLC-have been approved in several countries. The differences in multiple PD-L1 immunohistochemistry assay results in predicting the therapeutic response to combined chemoimmunotherapy in patients with NSCLC remain unclear.
Methods: In this multicenter prospective observational study, we monitored 70 patients with advanced NSCLC treated with combined chemoimmunotherapy at 10 institutions in Japan. The expression of PD-L1 in pretreatment tumors was evaluated using the 22C3, 28-8, and SP142 assays in all patients.
Results: The PD-L1 level in tumor cells determined using the 22C3 assay was the highest among the three assays performed with different antibodies. According to the 22C3 assay results, the PD-L1 tumor proportion score greater than or equal to 50% group had a significantly longer progression-free survival period than the PD-L1 tumor proportion score less than 50% group. Nevertheless, the other assays did not reveal remarkable differences in the objective response rate or progression-free survival.
Conclusions: In our study, PD-L1 expression determined using the 22C3 assay was more correlated with the therapeutic response of patients with NSCLC treated with combined chemoimmunotherapy than that determined using the 28-8 and SP142 assays. Therefore, the 22C3 assay may be useful for clinical decision-making for patients with NSCLC treated with combined chemoimmunotherapy. Trial registration number: UMIN 000043958.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
JTO clinical and research reports - 5(2024), 3 vom: 30. März, Seite 100644 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Katayama, Yuki [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chemoimmunotherapy |
|---|
| Anmerkungen: |
Date Revised 07.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.jtocrr.2024.100644 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369344251 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369344251 | ||
| 003 | DE-627 | ||
| 005 | 20240307232707.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240306s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jtocrr.2024.100644 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1319.xml |
| 035 | |a (DE-627)NLM369344251 | ||
| 035 | |a (NLM)38444594 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Katayama, Yuki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparing Three Different Anti-Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC |b A Prospective Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 07.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 The Authors. | ||
| 520 | |a Introduction: Multiple programmed death-ligand 1 (PD-L1) immunohistochemistry assays performed using different antibodies including DAKO 22C3, DAKO 28-8, and Ventana SP142 PD-L1-predictive markers for response to various immune checkpoint inhibitors in NSCLC-have been approved in several countries. The differences in multiple PD-L1 immunohistochemistry assay results in predicting the therapeutic response to combined chemoimmunotherapy in patients with NSCLC remain unclear | ||
| 520 | |a Methods: In this multicenter prospective observational study, we monitored 70 patients with advanced NSCLC treated with combined chemoimmunotherapy at 10 institutions in Japan. The expression of PD-L1 in pretreatment tumors was evaluated using the 22C3, 28-8, and SP142 assays in all patients | ||
| 520 | |a Results: The PD-L1 level in tumor cells determined using the 22C3 assay was the highest among the three assays performed with different antibodies. According to the 22C3 assay results, the PD-L1 tumor proportion score greater than or equal to 50% group had a significantly longer progression-free survival period than the PD-L1 tumor proportion score less than 50% group. Nevertheless, the other assays did not reveal remarkable differences in the objective response rate or progression-free survival | ||
| 520 | |a Conclusions: In our study, PD-L1 expression determined using the 22C3 assay was more correlated with the therapeutic response of patients with NSCLC treated with combined chemoimmunotherapy than that determined using the 28-8 and SP142 assays. Therefore, the 22C3 assay may be useful for clinical decision-making for patients with NSCLC treated with combined chemoimmunotherapy. Trial registration number: UMIN 000043958 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chemoimmunotherapy | |
| 650 | 4 | |a Non–small cell lung cancer | |
| 650 | 4 | |a PD-L1 | |
| 650 | 4 | |a Prospective analysis | |
| 650 | 4 | |a Therapeutic response | |
| 700 | 1 | |a Yamada, Tadaaki |e verfasserin |4 aut | |
| 700 | 1 | |a Morimoto, Kenji |e verfasserin |4 aut | |
| 700 | 1 | |a Fujii, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Morita, Satomi |e verfasserin |4 aut | |
| 700 | 1 | |a Tanimura, Keiko |e verfasserin |4 aut | |
| 700 | 1 | |a Takeda, Takayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Okada, Asuka |e verfasserin |4 aut | |
| 700 | 1 | |a Shiotsu, Shinsuke |e verfasserin |4 aut | |
| 700 | 1 | |a Chihara, Yusuke |e verfasserin |4 aut | |
| 700 | 1 | |a Hiranuma, Osamu |e verfasserin |4 aut | |
| 700 | 1 | |a Yamada, Takahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Ota, Takahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Harada, Taishi |e verfasserin |4 aut | |
| 700 | 1 | |a Hasegawa, Isao |e verfasserin |4 aut | |
| 700 | 1 | |a Iwasaku, Masahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Tokuda, Shinsaku |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Noriyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Miyagawa-Hayashino, Aya |e verfasserin |4 aut | |
| 700 | 1 | |a Takayama, Koichi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JTO clinical and research reports |d 2020 |g 5(2024), 3 vom: 30. März, Seite 100644 |w (DE-627)NLM315014199 |x 2666-3643 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2024 |g number:3 |g day:30 |g month:03 |g pages:100644 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jtocrr.2024.100644 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2024 |e 3 |b 30 |c 03 |h 100644 | ||